


Synthesis of Simeprevir (*Olysis*[®]; *Sovriad*[®])

Presented by: Katie Boknevit, Liu group, Boston College



Simeprevir

- Drug discovered and developed at Medivir (which was acquired by Janssen)
- Co-developed by a subsidiary of Johnson & Johnson, Tibotec, and Pharmasset (which is now Gilead)
- Simeprevir is a hepatitis C viral (HCV) NS3/4A protease inhibitor used to treat chronic HCV infection in combination with ribavirin and pegylated interferon- α .
- Drug approved for use in Japan, Canada, and the U.S.

References: Ding, H. X. *et al. Bioorg. Med. Chem.* **2015**, *23*, 1895–1922.

Rosenquist, Å. *et al. J. Med. Chem.* **2014**, *57*, 1673–1693.

Raboisson, P. *et al. Bioorg. Med. Chem. Lett.* **2008**, *18*, 4853–4858.

Retrosynthetic Analysis

